InnovaRx Innova Health Strategies

L82.0

Inflamed seborrheic keratosis

Billable FY2026 2025-10-01 → 2026-09-30
Exclusions 11 never code together
L82code
Excludes2
  • seborrheic dermatitis (L21.-)L21.-
L00-L99chapter
Excludes2
  • certain conditions originating in the perinatal period (P04-P96)P04-P96
  • certain infectious and parasitic diseases (A00-B99)A00-B99
  • complications of pregnancy, childbirth and the puerperium (O00-O9A)O00-O9A
  • congenital malformations, deformations, and chromosomal abnormalities (Q00-Q99)Q00-Q99
  • endocrine, nutritional and metabolic diseases (E00-E88)E00-E88
  • lipomelanotic reticulosis (I89.8)I89.8
  • neoplasms (C00-D49)C00-D49
  • symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified (R00-R94)R00-R94
  • systemic connective tissue disorders (M30-M36)M30-M36
  • viral warts (B07.-)B07.-

Excludes2 — not included here, but the patient may have both. Code both when documented.

Instructional notes 3
L82code
Includes
  • basal cell papilloma
  • dermatosis papulosa nigra
  • Leser-Trélat disease
Index entries leading here 6
  • Acanthosis (acquired) (nigricans) L83
  • Papilloma — see also Neoplasm, benign, by site
  • Verruca (due to HPV) (filiformis) (simplex) (viral) (vulgaris) B07.9
  • Leser-Trélat disease L82.1
  • Wart (due to HPV) (filiform) (infectious) (viral) B07.9
  • Keratosis L57.0
Alongside this code 1 same parent — L82
Medications 1

MED-RT files conditions by MeSH, which carves the world differently from ICD-10. These are name matches on this code's description, offered as candidates — not as an assertion that they are this code.

Additional references
AHA Coding Clinic® Licence required

Official coding advice for this code. Published by the American Hospital Association. Not included in this installation.

Risk adjustment

Maps to no condition category in any loaded model.

Presence is a property of the code. Untick a model to hide it everywhere.

This code

Billable
yes
Code set
FY2026
Parent
L82
Block
L80-L99
Siblings
1

Present FY2024–FY2027.